$27.00 $0.90 per serving
Product analysis
SAMe 400 mg supplies a compound involved in normal metabolism and may offer some joint symptom support, although the evidence is limited. Its unspecified form makes close comparison with other SAMe preparations harder.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality20
The specific SAMe form is not disclosed. That leaves its quality uncertain and limits close comparisons with other preparations.
Ingredient Transparency63
The SAMe amount is clear. Its specific form is missing, so the label is less useful for comparing preparations.
Value For Money40
SAMe offers limited value for the amount supplied. Its cost is less attractive without clearer preparation details.
Customer Satisfaction89
Customer feedback is very positive. Thousands of ratings provide a broad view of satisfaction, without proving health benefits.
Product Focus71
SAMe has a normal metabolic role and limited potential for joint symptom support. The serving is below the daily joint regimen described, and routine mood, stress or detoxification benefits remain uncertain.
- Format
Tablet - Container
- 30 Tablet(s)
- Per serving
- $0.90
- Also available
SAMe 400 mg$37.49- Customer rating
- 4.8 · 3,124 ratings
Goals
Impact
Moderate effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
Impact
Highest effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
SAMe Not classified
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
S-Adenosyl-Methionine | 400 mg |
SAMe · 400 mg OverallScore44
The serving provides 400 mg of SAMe at a moderate cost per 400 mg. Blister packaging is not documented. The active yield is not clearly separated from the salt weight.
How this ingredient is rated
Active Ingredient Quality & Bioavailability17
The SAMe salt form is not specified, leaving its stability unclear. Protective blister packaging is not documented, so moisture protection is unclear.
Stabilized Salt Form
The SAMe salt form is not specified, leaving its stability unclear.
Packaging Integrity
Protective blister packaging is not documented, so moisture protection is unclear.
Dose, Safety & Label Transparency72
A serving lists 400 mg of SAMe. The amount is not clearly distinguished as active SAMe versus salt weight.
Active Dosage Strength
A serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The amount is not clearly distinguished as active SAMe versus salt weight.
Value40
The cost per 400 mg of SAMe is moderate. Enteric coating or delayed release is not documented, leaving protection from stomach acid uncertain.
Price Per 400mg Active Dose
The cost per 400 mg of SAMe is moderate. Enteric coating or delayed release is not documented, leaving protection from stomach acid uncertain.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
- Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
- Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
- A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
- Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
- Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
- S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
- Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
- Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
- S-adenosylmethionine blood levels in major depression: changes with drug treatment.
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.